A Phase 1, Dose-escalation Study of MEDI-551, a Humanized Monoclonal Antibody Directed Against CD19, in Adult Subjects With Relapsed or Refractory Advanced B-Cell Malignancies
To determine the maximum tolerated dose (MTD) or optimal biologic dose (OBD) of MEDI-551 in
subjects with relapsed or refractory advanced B-cell malignancies.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To evaluate the MTD or OBD of MEDI-551 in subjects with relapsed or refractory advanced B-cell malignancies and to determine the preliminary safety profile in these populations.
Study Day 28
Trishna Goswami, M.D.
United States: Food and Drug Administration
|Research Site||Alabaster, Alabama|
|Research Site||Anaheim, California|
|Research Site||Washington, District of Columbia|
|Research Site||Boca Raton, Florida|
|Research Site||Arlington Heights, Illinois|
|Research Site||Abilene, Texas|
|Research Site||Clarksburg, West Virginia|